Vitamin c and iron combo takes on glioblastoma in first human test
NCT ID NCT04900792
First seen Nov 06, 2025 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This early-phase trial tests whether adding high-dose vitamin C and an iron drug (ferumoxytol) to standard radiation and chemotherapy can help control glioblastoma, an aggressive brain tumor. Seventeen adults with newly diagnosed glioblastoma will receive the combination. The main goal is to find a safe dose, but researchers will also track how long patients live without the tumor growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Radiation Oncology at University of Iowa
Iowa City, Iowa, 52242, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vitamin C (ascorbate) and an iron drug (ferumoxytol)
What this could lead to
If this works, it could point toward a way to make standard treatment for glioblastoma more effective, potentially helping patients live longer.
What could go wrong
This is a very early, small trial with only 17 people. It is designed mainly to test safety, not to prove the treatment works. The added drugs may cause side effects or not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.